The clinical trials KEYNOTE-040 and CheckMate 141 evaluated the anti-PD-1 antibodies pembrolizumab and nivolumab, respectively, in the treatment of R/M HNSCC and demonstrated remarkable results (4, 5). The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.